These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22658745)

  • 1. Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome.
    Ruparelia A; Pearn ML; Mobley WC
    Curr Opin Neurobiol; 2012 Oct; 22(5):880-6. PubMed ID: 22658745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathways to cognitive deficits in Down syndrome.
    Sturgeon X; Le T; Ahmed MM; Gardiner KJ
    Prog Brain Res; 2012; 197():73-100. PubMed ID: 22541289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.
    Gardiner KJ
    Drug Des Devel Ther; 2015; 9():103-25. PubMed ID: 25552901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.
    Faizi M; Bader PL; Tun C; Encarnacion A; Kleschevnikov A; Belichenko P; Saw N; Priestley M; Tsien RW; Mobley WC; Shamloo M
    Neurobiol Dis; 2011 Aug; 43(2):397-413. PubMed ID: 21527343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Perspectives for the Rescue of Cognitive Disability in Down Syndrome.
    Bartesaghi R; Haydar TF; Delabar JM; Dierssen M; Martínez-Cué C; Bianchi DW
    J Neurosci; 2015 Oct; 35(41):13843-52. PubMed ID: 26468184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down syndrome: genes, model systems, and progress towards pharmacotherapies and clinical trials for cognitive deficits.
    Busciglio J; Capone G; O'Bryan J; Gardiner KJ
    Cytogenet Genome Res; 2013; 141(4):260-71. PubMed ID: 24008277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience-dependent reduction of soluble β-amyloid oligomers and rescue of cognitive abilities in middle-age Ts65Dn mice, a model of Down syndrome.
    Sansevero G; Begenisic T; Mainardi M; Sale A
    Exp Neurol; 2016 Sep; 283(Pt A):49-56. PubMed ID: 27288239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome.
    Kirsammer G; Jilani S; Liu H; Davis E; Gurbuxani S; Le Beau MM; Crispino JD
    Blood; 2008 Jan; 111(2):767-75. PubMed ID: 17901249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aging and intellectual disability: insights from mouse models of Down syndrome.
    Ruparelia A; Pearn ML; Mobley WC
    Dev Disabil Res Rev; 2013; 18(1):43-50. PubMed ID: 23949828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors.
    Heller HC; Salehi A; Chuluun B; Das D; Lin B; Moghadam S; Garner CC; Colas D
    Neurobiol Learn Mem; 2014 Dec; 116():162-71. PubMed ID: 25463650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.
    Rueda N; Flórez J; Martínez-Cué C
    Neural Plast; 2012; 2012():584071. PubMed ID: 22685678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
    Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC
    Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.
    Stringer M; Abeysekera I; Dria KJ; Roper RJ; Goodlett CR
    Pharmacol Biochem Behav; 2015 Nov; 138():70-9. PubMed ID: 26363314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: pharmacological intervention for Down syndrome cognitive deficits: emerging drug targets.
    Montesinos ML
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):6-7. PubMed ID: 24152331
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome.
    Giacomini A; Stagni F; Emili M; Guidi S; Salvalai ME; Grilli M; Vidal-Sanchez V; Martinez-Cué C; Bartesaghi R
    Brain Res Bull; 2018 Jun; 140():378-391. PubMed ID: 29935232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forebrain Shh overexpression improves cognitive function and locomotor hyperactivity in an aneuploid mouse model of Down syndrome and its euploid littermates.
    Gao FJ; Klinedinst D; Fernandez FX; Cheng B; Savonenko A; Devenney B; Li Y; Wu D; Pomper MG; Reeves RH
    Acta Neuropathol Commun; 2021 Aug; 9(1):137. PubMed ID: 34399854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.
    Lee SE; Duran-Martinez M; Khantsis S; Bianchi DW; Guedj F
    Trends Mol Med; 2020 Feb; 26(2):150-169. PubMed ID: 31706840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
    Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice.
    Yu T; Liu C; Belichenko P; Clapcote SJ; Li S; Pao A; Kleschevnikov A; Bechard AR; Asrar S; Chen R; Fan N; Zhou Z; Jia Z; Chen C; Roder JC; Liu B; Baldini A; Mobley WC; Yu YE
    Brain Res; 2010 Dec; 1366():162-71. PubMed ID: 20932954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome.
    Martinez de Lagran M; Elizalde-Torrent A; Paredes R; Clotet B; Dierssen M
    J Cell Mol Med; 2022 Aug; 26(15):4210-4215. PubMed ID: 35762509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.